
NEW ORLEANS--The next decade will be a critical time for translating new cancer vaccine approaches into standard therapies, said Drew Pardoll, MD, PhD, of Johns Hopkins University School of Medicine. In a talk at the plenary session of the 89th annual meeting of the American Association for Cancer Research, Dr. Pardoll noted that antigen-based anticancer vaccines offer perhaps the most promising approach.
